Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum CICC P0001 + lactobacillus plantarum P-8 + bifidobacterium infantum CICC 6069 + lactobacillus reuteri CICC 6132
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This oral probiotic mixture is a live biotherapeutic product (LBP) composed of four specific bacterial strains: *Bifidobacterium longum* CICC P0001, *Lactobacillus plantarum* P-8, *Bifidobacterium infantum* CICC 6069, and *Lactobacillus reuteri* CICC 6132. Developed by the Chinese PLA General Hospital, the formulation is designed to modulate the gut microbiota as a therapeutic intervention for Tourette's syndrome in children. The treatment rationale is based on the gut-brain axis, suggesting that the restoration of microbial balance and the subsequent modulation of microbial metabolites can influence neurological pathways and neurotransmitter signaling associated with tic disorders. It is currently being evaluated in clinical trials to assess its efficacy in reducing tic severity and improving behavioral outcomes.
- Other names
- Probiotic mixture for Tourette's syndromeFour-strain probiotic mixture
Beyond the preview
Go deeper on bifidobacterium longum CICC P0001 + lactobacillus plantarum P-8 + bifidobacterium infantum CICC 6069 + lactobacillus reuteri CICC 6132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum CICC P0001 + lactobacillus plantarum P-8 + bifidobacterium infantum CICC 6069 + lactobacillus reuteri CICC 6132.